IGF-1 LR3 1mg Dosage Protocol

1. Preparation and Measurement

IGF-1 LR3 1mg With 1mL of Diluent

Add 1mL of bacteriostatic water to the vial. The resulting concentration is 1mg/mL. On a U-100 syringe, each unit contains 10mcg.

Preparation

1. Draw 1mL of bacteriostatic water using sterile equipment.
2. Let the liquid run slowly down the inside wall of the vial.
3. Gently swirl until dissolved. Do not shake.
4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated research protocols. Frequency: once daily.

Vial estimate: One 1mg vial contains approximately 50 administrations at the first listed amount or 20 at the final listed amount.

Practical Notes

• The table applies only to this vial prepared with exactly 1mL.
• Some entries are very small measurements; account for the accuracy of the measuring device.
• Record the amount, date, and preparation used.

3. Supplies Needed

• IGF-1 LR3 1mg vial.
• 1mL of bacteriostatic water per vial.
• Sterile U-100 syringes.
• Alcohol swabs.
• Sharps container.

4. Storage and Handling

• Keep unopened vials cool, dry, dark, and protected from moisture.
• After preparation, refrigerate at 2-8 degrees C.
• Protect from light and avoid repeated freeze-thaw cycles.
• Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

IGF-1 LR3 is a modified IGF-1 analogue developed to alter protein binding and biological persistence. Most supporting work is preclinical or laboratory based and does not establish a clinically validated human dose.

IGF-1 LR3 is not an approved therapeutic drug. The table records a circulated research convention for comparison, not a safety or efficacy recommendation.

Primary Research and Regulatory References

1. IGF-1 analogue binding and biological activity study
2. Long R3 IGF-I metabolism study
3. Long R3 IGF-I experimental response study